Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function
复制标题
非选择性β受体阻滞剂治疗晚期肝硬化：对总体生存率和肾功能影响的严格审查
作者：
S. Blasco;José Masegosa;S. Alonso;M. Gutiérrez;C. Fernández
前言非选择性β受体阻滞剂（NSBB）被广泛用于肝硬化患者食管静脉曲张出血的一级和二级预防。此外，有人认为NSBB的临床受益可能超出其血液动力学效应。最近，在难治性腹水或自发性细菌性腹膜炎患者中描述了一种潜在的有害作用。方法使用PubMed/MEDLINE、AMED、CINAHL和科克伦对照试验中心数据库对β受体阻滞剂和肝硬化生存率进行全面的文献检索。回顾了从1980年到2016年4月超过35年发表的全文手稿的相关性，并交叉检查了参考文献列表，以了解有关潜在NSBB影响的其他相关研究，特别是关注与生存和/或急性肾损伤（阿基）有关的研究。讨论拟议的审查将能够提供有价值的证据，以帮助决策在使用NSBB治疗晚期肝硬化，并强调了一些限制，在现有的证据，以指导未来的研究。
Introduction Non-selective β-blockers (NSBBs) are widely prescribed in patients with cirrhosis for primary and secondary prophylaxis of bleeding oesophageal varices. Furthermore, it has been suggested that the clinical benefits of NSBBs may extend beyond their haemodynamic effects. Recently, a potentially harmful effect has been described in patients with refractory ascites or spontaneous bacterial peritonitis. Methodology A comprehensive literature search on β-blockers and cirrhosis survival using the electronic databases PubMed/MEDLINE, AMED, CINAHL and the Cochrane Central Register of Controlled Trials. Full-text manuscripts published over more than 35 years, from 1980 to April 2016 were reviewed for relevance and reference lists were cross-checked for additional pertinent studies regarding potential NSBB effects, especially focused on those concerned with survival and/or acute kidney injury (AKI). Discussion The proposed review will be able to provide valuable evidence to help decision making in the use of NSBB for the treatment of advanced cirrhosis and highlights some limitations in existing evidence to direct future research.
DOI：
10.1016/s0015-6264(78)80335-6
发表时间：
1986
期刊：
The New Zealand medical journal
影响因子：
--
作者：
D. Woodfield
通讯作者：
D. Woodfield